MACSF

COMMUNIQUÉS West-GlobeNewswire

Arbor Biotechnologies Announces First Patient Dosed at Mayo Clinic in the redePHine Phase 1/2 Study of ABO-101, an Investigational Gene Editing Treatment for Primary Hyperoxaluria Type 1
30/07/2025
- ABO-101 was well tolerated with no serious adverse events or dose-limiting toxicities reported in the 28-days following dosing - Phase 1/2 redePHine study ( NCT06839235) dose escalation ongoing with enrollment at Mayo [...]
Life Backup Plan by Galacxia, Inc Announces $45K in Funding to Expand Its AI-Powered Health and Safety App
30/07/2025
Aliso Viejo, CA, July 30, 2025 (GLOBE NEWSWIRE) -- Life Backup Plan by Galacxia, Inc , redefining how individuals and care systems manage everything from emergencies to healthcare communication, today announced $45,000 [...]
Outset Medical Names First Chief Nursing Officer
30/07/2025
Accomplished nursing executive to lead Outset’s clinical education and support programs for the dialysis nursing community SAN JOSE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset [...]
BrainsWay Champions TMS Education with Sponsorship of Two Free CME Courses for Mental Health Professionals
30/07/2025
BURLINGTON, Mass. and JERUSALEM, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- BrainsWay , a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, is proud to announce its [...]
New Progyny Study Reveals Gap Between Perceptions and Realities in Women’s Health Benefits Coverage
30/07/2025
Increased awareness of expanded women’s health and family building solutions has led to a growing disconnect between most wanted employee benefits and employer offerings NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- [...]
FDA Provides Trethera Clearance to Initiate TRE-515 Clinical Trial in Healthy Volunteers to Study Food Effect and Biomarkers
30/07/2025
LOS ANGELES, July 30, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today that [...]
Vystar Introduces New RxAir-800 Replacement Cartridge Extended Life UV-C Bulb
30/07/2025
New RxAir400 Pro UV-C bulb replacement cartridge provides 18,000 vs 9,000 hr. use. Worcester, MA, July 30, 2025 (GLOBE NEWSWIRE) -- With heightened concern about protection from harmful airborne viruses, Vystar [...]
Rakovina Therapeutics Highlights Long-Standing Collaboration with the University of British Columbia and the Vancouver Prostate Centre
30/07/2025
VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered [...]
Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development
30/07/2025
Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025: Dr. Falk Pharma GmbH and Allianthera (Suzhou) Biopharmaceuticals Co., Ltd. Announce Strategic Partnership to Develop a Novel AhR Agonist for the [...]
KFSHRC Advances Robotic Surgery with a Successful Ivor Lewis Esophagectomy
30/07/2025
RIYADH, Saudi Arabia, July 30, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) in Riyadh successfully performed a robotic Ivor Lewis esophagectomy, the first of its kind in the [...]
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
30/07/2025
License agreement supports Madrigal’s pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra™ (resmetirom) Combining Rezdiffra with the oral GLP-1, [...]
Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants
30/07/2025
MINNEAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of [...]
Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components
30/07/2025
On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy. Q2 2025 shows 10 th consecutive quarter of year-over-year (YoY) revenue growth; Revenues of $4.2 billion, +1% in local [...]
Avacta to Present New FAP Dox (AVA6000) Data at the European Society for Medical Oncology (ESMO) Congress
30/07/2025
LONDON and PHILADELPHIA, July 30, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, ‘the Company’), a life sciences company developing innovative, targeted oncology drugs, today announces that the Company will [...]
BioStem Technologies to Host Second Quarter 2025 Financial Results Conference Call on August 14, 2025
30/07/2025
Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and [...]
Novasight™ Hybrid Imaging System Featured in Published JSCAI Case Report Demonstrating Superior Diagnosis and Precision-Guided Therapy in Complex Coronary Case
30/07/2025
TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Inc. (TSXV: CNVI) (OTCQB: CNVIF), a leader in hybrid intravascular imaging, is pleased to announce the publication of a compelling case report in the Journal of [...]
Amarin Reports Second Quarter 2025 Financial Results
30/07/2025
-- European Partnership with Recordati Established to Maximize VAZKEPA ® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12 Months -- -- Q2 2025 [...]
Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025
30/07/2025
SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other metabolic health [...]
EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025
30/07/2025
WATERTOWN, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with [...]

Pages